There have been many trials proving surgical intervention does indeed reduce the risk of progressive glaucoma damage for our patients. These include Treatment vs No Treatment studies as well as studies that compare different types of treatment. In this episode, I talk with Steve Gedde, from the University of Miami's Bascom Palmer Eye Institute, about lessons learned from these clinical trials.
Read MoreIn this episode, I talk with Daniel Laroche. We have crossed paths for many years at conferences having both started our practices at the same time, but this was the first time we sat down to record our conversation. Daniel Laroche is Director of Glaucoma Services and President of Advanced Eyecare of New York. He is affiliated with the New York Eye and Ear Infirmary, and Assistant Professor of Ophthalmology at the Mount Sinai School of Medicine, New York.
Read MoreIn this episode, I talk with Gus DeMoraes, a frequent guest of the pod. Gus is Associate Professor of Ophthalmology at Columbia University where he serves as Medical Director of Clinical Trials. When we originally sat down to record this way back in March 2019, he had just presented some of the work he had done in collaboration with Don Hood. This has now appeared on Humphrey perimeters as the 24-2C testing strategy and is becoming a new the standard of care. It is based on reports in recent years that glaucoma damage often occurs in the macular area but missed because the standard 24-2 testing strategy only tests in 6 degree increments. These early central glaucomatous defects are often hidden between the test points.
Read MoreIn this episode, I talk with Won Kim, a glaucoma colleague based at Walter Reed National Military Medical Center and Hospital in Bethesda, Maryland, about why he has been combining multiple minimally invasive glaucoma procedures in patients who have failed traditional glaucoma surgery.
Read MoreThe goal of the late Dave Epstein was to find a drug that treats the cause of glaucoma by improving trabecular meshwork outflow. After many years of research, Aerie Pharmaceuticals was formed and refined a Rho Kinase inhibitor called Netarsudil. In April 2018 this came to market as Rhopressa and March 2019, combined with latanoprost, as Roclatan. Today I’m talking with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals…and we’re Talking About Glaucoma.
Read MoreIn this episode, I talk with Murray Johnstone from Seattle about pulsatile flow through the Trabecular Meshwork and collector channels. We discuss the imaging improvements over the years that have made this possible including the latest phase-based OCT scans that result in nanometre resolution instead of the micrometre resolution of spectral domain scans that most of us are using in clinical practice.
Read MoreI started this site in 2009 to write about Glaucoma, Health IT (EMR, EHR), Technology and to host my podcast series "Talking About Glaucoma." There is a shortcut to this blog to make it easier to find http://iguy.tv/blog.
I am a glaucoma sub-specialized Ophthalmologist and have a full time clinical practice at the Dartmouth-Hitchcock Clinic of the Geisel School of Medicine in Hanover, NH. I have a longtime interest in the use of technology to help in medical care as well as in Education. In addition, I was a very early adopter and developer of Electronic Medical Record systems who has lectured internationally on the topic of making the transition to EMRs in daily practice.
Copyright © 2009-2018, Robert M Schertzer, MD, MEd, FRCSC. All rights reserved.
